PD-L1 Testing Market Research Report 2033

Report Description

PD-L1 Testing Market Outlook

According to our latest research, the global PD-L1 testing market size reached USD 1.34 billion in 2024, driven by the expanding adoption of immunotherapy and the rising incidence of cancer worldwide. The market is experiencing robust growth, with a compound annual growth rate (CAGR) of 9.8% projected from 2025 to 2033. By the end of 2033, the market is forecasted to achieve a value of USD 3.13 billion. One of the primary factors propelling this growth is the increasing clinical relevance of PD-L1 testing in guiding personalized cancer treatment, particularly in advanced and metastatic cases.

The significant growth of the PD-L1 testing market is largely fueled by the rising prevalence of cancer, particularly non-small cell lung cancer (NSCLC), melanoma, and other solid tumors where immunotherapy has become a standard of care. As cancer rates continue to climb globally, the necessity for precise biomarkers that can predict patient response to immune checkpoint inhibitors has become paramount. PD-L1 testing plays a critical role in stratifying patients who are most likely to benefit from therapies targeting the PD-1/PD-L1 axis, enabling oncologists to tailor treatments and improve clinical outcomes. Furthermore, the increasing awareness among healthcare professionals about the advantages of personalized medicine is accelerating the adoption of PD-L1 assays in both developed and emerging markets.

Technological advancements in assay development have also significantly contributed to the market’s expansion. The evolution of immunohistochemistry (IHC) and polymerase chain reaction (PCR) technologies has enhanced the sensitivity, specificity, and reproducibility of PD-L1 testing. These innovations have led to the development of companion diagnostic tests approved by regulatory agencies, further driving clinical adoption. Additionally, the integration of digital pathology and artificial intelligence in PD-L1 scoring is streamlining workflow efficiencies and reducing inter-observer variability, thus improving diagnostic accuracy. The continuous investment in research and development by diagnostic companies is also resulting in the launch of novel and more reliable PD-L1 assays.

Another notable growth factor is the expanding application of PD-L1 testing beyond traditional indications. While non-small cell lung cancer remains the leading application, there is a growing body of evidence supporting the use of PD-L1 as a predictive biomarker in a variety of malignancies, including bladder cancer, head and neck cancer, and melanoma. As clinical guidelines evolve and more immune checkpoint inhibitors receive regulatory approval for new cancer types, the demand for PD-L1 testing is expected to rise across multiple oncology segments. This trend is particularly pronounced in research settings, where PD-L1 expression is being investigated as a potential biomarker for novel immunotherapeutic agents.

From a regional perspective, North America currently dominates the PD-L1 testing market, accounting for the largest share in 2024. This leadership is attributed to the high prevalence of cancer, advanced healthcare infrastructure, and favorable reimbursement policies for companion diagnostics. Europe follows closely, supported by robust clinical research activity and increasing adoption of personalized medicine. Meanwhile, the Asia Pacific region is poised for the fastest growth over the forecast period, fueled by rising cancer incidence, improving healthcare access, and growing investments in healthcare technology. Latin America and the Middle East & Africa, while smaller in market share, are expected to witness steady growth due to increasing awareness and gradual improvements in diagnostic capabilities.

Get Free Sample Report

Product Type Analysis

The PD-L1 testing market by product type is segmented into immunohistochemistry (IHC) assays, polymerase chain reaction (PCR) assays, and others. Immunohistochemistry (IHC) assays currently represent the largest segment, owing to their widespread clinical adoption and established role as the gold standard for PD-L1 detection in tumor tissues. IHC assays are routinely utilized in pathology laboratories for the qualitative and semi-quantitative analysis of PD-L1 expression, particularly in non-small cell lung cancer and other solid tumors. The increasing number of FDA-approved companion diagnostic IHC assays, such as those developed by Dako and Ventana, further solidifies this segment’s dominance. The high specificity, reproducibility, and compatibility with formalin-fixed paraffin-embedded (FFPE) tissue samples contribute to the segment’s continued growth.

Polymerase chain reaction (PCR) assays are gaining traction as a complementary technology, offering quantitative analysis of PD-L1 gene expression at the mRNA level. PCR-based assays provide several advantages, including higher sensitivity and the capability to detect low-abundance transcripts, which is particularly valuable in cases where tissue samples are limited. The growing preference for minimally invasive testing and liquid biopsy approaches is also fostering the adoption of PCR assays in both clinical and research environments. As more research elucidates the correlation between PD-L1 mRNA expression and therapeutic response, PCR assays are expected to play an increasingly important role in the diagnostic landscape.

The "others" category encompasses emerging technologies such as next-generation sequencing (NGS) and multiplex immunofluorescence assays, which are being explored for their potential to provide comprehensive biomarker profiling. These advanced platforms enable the simultaneous assessment of multiple immune-related markers, offering a more holistic view of the tumor microenvironment. Although currently limited to research and specialized clinical settings due to higher costs and complexity, these technologies are anticipated to gain wider acceptance as their clinical utility becomes further validated. The integration of artificial intelligence and digital pathology is also expected to enhance the accuracy and scalability of these novel assays.

Market dynamics within the product type segment are influenced by ongoing innovation, regulatory approvals, and the evolving landscape of companion diagnostics. The competition among assay developers to secure regulatory endorsements for their tests as companion diagnostics for new immunotherapeutic agents is intensifying. This trend not only improves the clinical relevance of PD-L1 testing but also stimulates further investment in assay development. As healthcare providers increasingly seek standardized, high-throughput, and cost-effective solutions, the market is witnessing a shift towards automated platforms and integrated diagnostic systems that streamline laboratory workflows.

Report Scope

Application Analysis

The application segment of the PD-L1 testing market is led by non-small cell lung cancer (NSCLC), which accounts for the largest share due to the high prevalence of the disease and the established role of PD-L1 as a predictive biomarker for immune checkpoint inhibitor therapy. The use of PD-L1 testing in NSCLC has been widely endorsed by clinical guidelines, and it is now a routine part of diagnostic workups for patients being considered for pembrolizumab, nivolumab, and other PD-1/PD-L1 inhibitors. The growing body of clinical evidence supporting the correlation between PD-L1 expression and therapeutic response in NSCLC continues to drive demand for testing in this application.

Melanoma represents another significant application area, where PD-L1 testing is increasingly being utilized to guide immunotherapy decisions. Although the relationship between PD-L1 expression and response to checkpoint inhibitors in melanoma is more complex compared to NSCLC, ongoing research and clinical trials are shedding light on the potential utility of PD-L1 as a biomarker in this setting. The emergence of combination immunotherapy regimens and the approval of new agents are further expanding the scope of PD-L1 testing in melanoma management.

Bladder cancer and head and neck cancer are also notable application segments, reflecting the expanding indications for immune checkpoint inhibitors in these malignancies. Regulatory approvals for PD-1/PD-L1 inhibitors in advanced bladder cancer have prompted the integration of PD-L1 testing into clinical practice, particularly for patient selection and prognostication. Similarly, in head and neck squamous cell carcinoma, PD-L1 testing is increasingly used to identify candidates for immunotherapy, with growing adoption in both academic and community practice settings.

The "others" category encompasses a range of additional cancers, such as gastric, esophageal, and renal cell carcinoma, where PD-L1 testing is being explored as a potential predictive biomarker. As the clinical evidence base expands and more immune checkpoint inhibitors are approved for new cancer types, the application landscape for PD-L1 testing is expected to broaden further. Research institutes and pharmaceutical companies are actively investigating the role of PD-L1 expression in predicting response to novel immunotherapeutic agents, which is likely to drive future growth in this segment.

End User Analysis

The end user segment of the PD-L1 testing market is dominated by hospitals, which account for the largest share due to their central role in cancer diagnosis, treatment, and patient management. Hospitals typically house comprehensive pathology laboratories equipped with advanced diagnostic technologies, enabling them to perform high-volume PD-L1 testing as part of routine clinical workflows. The increasing adoption of multidisciplinary care models and tumor boards in hospital settings further supports the integration of PD-L1 testing into personalized oncology protocols.

Diagnostic laboratories, including both independent and reference labs, represent a rapidly growing end user segment. These laboratories offer specialized testing services to hospitals, clinics, and oncologists who may lack in-house capabilities for complex biomarker assays. The trend towards laboratory consolidation and the expansion of centralized diagnostic services are driving the adoption of PD-L1 testing in this segment. Diagnostic laboratories are also at the forefront of implementing new assay technologies, such as automated IHC platforms and digital pathology solutions, to enhance testing efficiency and accuracy.

Research institutes play a crucial role in advancing the understanding of PD-L1 biology and its clinical implications. These institutions are actively involved in translational research, clinical trials, and biomarker discovery, contributing to the development of novel PD-L1 assays and the identification of new therapeutic indications. The growing collaboration between academic centers, pharmaceutical companies, and diagnostic manufacturers is fostering innovation and accelerating the translation of research findings into clinical practice.

The "others" category includes specialty clinics, cancer centers, and contract research organizations (CROs) that provide PD-L1 testing services as part of clinical research or specialized patient care. As the demand for personalized oncology solutions continues to rise, these entities are increasingly incorporating PD-L1 testing into their service portfolios. The expansion of clinical trial networks and the proliferation of early-phase studies evaluating novel immunotherapeutics are expected to further drive growth in this end user segment.

Opportunities & Threats

The PD-L1 testing market presents numerous opportunities for growth and innovation. One of the most promising opportunities lies in the development of multiplex and multi-omic diagnostic platforms that can simultaneously assess PD-L1 expression alongside other immune-related biomarkers. These integrated solutions have the potential to provide a more comprehensive understanding of the tumor microenvironment, enabling more precise patient stratification and personalized treatment planning. Additionally, the increasing adoption of digital pathology and artificial intelligence (AI) in diagnostic workflows is expected to enhance the accuracy, reproducibility, and scalability of PD-L1 testing, opening new avenues for market expansion.

Another significant opportunity is the expansion of PD-L1 testing into emerging markets, particularly in Asia Pacific and Latin America. These regions are experiencing a surge in cancer incidence and are investing heavily in healthcare infrastructure and diagnostic capabilities. As awareness of personalized medicine grows and access to advanced diagnostic technologies improves, there is substantial potential for market penetration in these geographies. Strategic partnerships between diagnostic companies, healthcare providers, and government agencies can further facilitate the adoption of PD-L1 testing and drive sustainable market growth.

Despite the favorable outlook, the PD-L1 testing market faces certain restraining factors. One of the primary challenges is the variability in assay performance and interpretation, which can lead to inconsistent results and impact clinical decision-making. The lack of standardized scoring criteria and cut-off values for PD-L1 expression across different assays and cancer types remains a significant barrier to widespread adoption. Additionally, the high cost of advanced diagnostic technologies and limited reimbursement in some regions may hinder market growth, particularly in resource-constrained settings. Addressing these challenges will require ongoing collaboration among stakeholders to establish consensus guidelines and ensure equitable access to high-quality PD-L1 testing.

Regional Outlook

North America continues to lead the global PD-L1 testing market, accounting for approximately USD 570 million in 2024, which represents the largest regional share. The region’s dominance is underpinned by a high burden of cancer, well-established healthcare infrastructure, and a strong focus on precision medicine. The widespread adoption of companion diagnostics, favorable reimbursement policies, and the presence of leading diagnostic companies further support market growth in North America. The United States, in particular, is at the forefront of clinical research and regulatory approvals, driving the integration of PD-L1 testing into routine clinical practice.

Europe holds the second-largest share of the PD-L1 testing market, with a market size of USD 390 million in 2024. The region benefits from robust clinical research activity, increasing investments in healthcare technology, and the growing implementation of personalized medicine initiatives. Countries such as Germany, France, and the United Kingdom are leading adopters of PD-L1 testing, supported by comprehensive cancer care networks and active participation in international clinical trials. The European market is expected to maintain steady growth, with a projected CAGR of 9.2% through 2033, as regulatory agencies continue to endorse companion diagnostics for new immunotherapeutic agents.

The Asia Pacific region is poised for the fastest growth, with a market size of USD 260 million in 2024 and a projected CAGR exceeding 11% over the forecast period. This rapid expansion is driven by rising cancer incidence, improving access to advanced diagnostics, and increasing healthcare spending in key markets such as China, Japan, and India. Government initiatives to enhance cancer screening and early detection, coupled with growing collaborations between local and international diagnostic companies, are accelerating the adoption of PD-L1 testing in the region. Latin America and the Middle East & Africa, with market sizes of USD 70 million and USD 30 million respectively, are expected to witness gradual growth as healthcare infrastructure and awareness continue to improve.

Get Free Sample Report

Competitor Outlook

The PD-L1 testing market is characterized by intense competition and a dynamic landscape, with several established and emerging players vying for market share. The competitive environment is defined by continuous innovation, strategic partnerships, and a strong emphasis on securing regulatory approvals for companion diagnostic assays. Leading diagnostic companies are investing heavily in research and development to enhance the sensitivity, specificity, and ease of use of their PD-L1 assays, while also expanding their portfolios to cover new cancer indications and testing platforms. The increasing importance of companion diagnostics in immunotherapy regimens has further intensified competition, as manufacturers strive to align their products with the latest therapeutic advances.

Strategic collaborations and partnerships between diagnostic companies, pharmaceutical firms, and healthcare providers are a hallmark of the market, aimed at accelerating assay development, expanding market reach, and improving clinical integration. These alliances enable the co-development of companion diagnostics for novel immunotherapeutic agents, facilitating faster regulatory approvals and broader clinical adoption. The trend towards consolidation in the diagnostic industry is also evident, with larger players acquiring specialized assay developers to strengthen their market position and enhance their technological capabilities.

The adoption of digital pathology and artificial intelligence is emerging as a key differentiator among competitors, with companies investing in advanced image analysis algorithms and automated scoring systems to improve the accuracy and reproducibility of PD-L1 testing. The integration of these technologies into existing diagnostic platforms is enabling laboratories to process higher volumes of tests with greater consistency, thereby enhancing operational efficiency and reducing turnaround times. As the market continues to evolve, the ability to offer comprehensive, integrated diagnostic solutions will be a critical success factor for leading players.

Major companies operating in the PD-L1 testing market include Agilent Technologies (Dako), Roche Diagnostics (Ventana Medical Systems), Thermo Fisher Scientific, Merck KGaA, and Abbott Laboratories. Agilent Technologies, through its Dako division, is a pioneer in IHC-based PD-L1 assays and has secured multiple regulatory approvals for companion diagnostics. Roche Diagnostics, with its Ventana platform, is another leading player, known for its innovative automated IHC solutions and strong presence in both clinical and research settings. Thermo Fisher Scientific offers a broad portfolio of molecular and immunoassay platforms, while Merck KGaA is actively involved in the development of novel PD-L1 testing technologies and strategic collaborations with pharmaceutical partners. Abbott Laboratories is expanding its presence in the molecular diagnostics space, leveraging its expertise in PCR and NGS technologies to address emerging needs in PD-L1 testing.

These companies are distinguished by their commitment to advancing diagnostic science, expanding global reach, and fostering innovation through strategic investments and partnerships. As the PD-L1 testing market continues to grow and diversify, the competitive landscape is expected to remain dynamic, with ongoing developments in assay technology, regulatory approvals, and clinical applications shaping the future of the industry.

Key Players

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Abbott Laboratories
• Bio-Techne Corporation
• PerkinElmer, Inc.
• Danaher Corporation
• Siemens Healthineers AG
• GE Healthcare
• Abcam plc
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• GenScript Biotech Corporation
• Cell Signaling Technology, Inc.
• Enzo Biochem, Inc.
• Leica Biosystems (a Danaher company)
• Ventana Medical Systems, Inc. (Roche)
• OriGene Technologies, Inc.
• Atlas Antibodies AB

Get Free Sample Report